The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein i antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients.

Comments on the article 'Acquired Activated Protein C Resistance Is Associated with the Co-Existence of Anti-Prothrombin Antibodies and Lupus Anticoagulant Activity in Patients with Systemic Lupus Erythematosus,' by J. Nojima and colleagues. Data published in the 'British Journal of Haematology'; Coexistence of lupus anticoagulant and anti-phrothrombin antibodies as a risk factor.